Research and Markets (http://www.researchandmarkets.com/research/92c9ad/the_future_of_auto)
has announced the addition of the "The Future of Autoimmune Diseases
Therapeutics - Market Forecasts to 2015, Competitive Benchmarking,
Product Pipeline and Deal Analysis" report to their offering.
"The Future of Autoimmune Diseases Therapeutics - Market Forecasts to
2015, Competitive Benchmarking, Product Pipeline and Deal Analysis"
provides an essential source of data and analysis on the global
autoimmune disease therapeutics market with coverage on the market
landscape, key market trends, market drivers and restraints. The report
identifies the key trends shaping and driving the dynamism in the global
autoimmune disease therapeutics market. The report also provides an
insight in to the prevalent competitive landscape, product pipeline
supplemented with key company profiles.
The Global Autoimmune Disease Therapeutics Market is Forecast to Show
Steady Growth over the Forecast Period
The global autoimmune disease therapeutics market was valued to be $32
billion in 2008 and expected to grow to $48 billion with a CAGR of 6% by
year 2015. Approximately 3.3 million patients received pharmacological
treatment for autoimmune diseases with average cost of therapy being
$12,545 per year. The patient volume appears to be increasing at a slow
rate of 0.6% per year. In addition, the average annual cost of therapy
for autoimmune therapeutics appears to be increasing at a higher rate
over the forecast period and is expected to reach an approximate value
of $13,400 by 2015. As a result, the autoimmune disease therapeutic
market value is going to see a steady increase over the time period 2008
- 2015.
Increasing Acceptance of Biologics as First Line of Treatment Set to
Increase the Average Treatment Costs for Autoimmune Disorders
The authors analyzed environmental and industry trends to assess the
market evolution. The therapeutic capabilities of biologics in
controlling and treating autoimmune complications are allowing
pharmaceutical manufacturers to commence label extensions of their
present portfolio of biologics for multiple autoimmune complications.
Biologics like Enbrel, Humira and Remicade have proved to be blockbuster
drug due to their higher efficacy profiles. These drugs have recently
gained popularity over the traditional treatment options. Currently the
market is dominated by the other traditional chemotherapies. In the year
2008 the biologics had a share of about 35% of the autoimmune market
with 65% owned by the traditional chemotherapy options. But the scenario
is expected to undergo a drastic change with time.
Presence of High levels of Unmet Need within Autoimmune Disease Sectors
The current therapeutic options available in the autoimmune sector
includes various kinds of treatment options like immunosuppressant,
anti-inflammatory drugs, anti-cancer drugs, anti- malarial drugs,
DMARDs, NSAIDs and most importantly the biologics. Even with this wide
variety of the available treatment options the autoimmune market sector
is facing a very high level of unmet patient need. The Biologics in the
various autoimmune disease sectors witness high levels of efficacy but
are not very safe. The other Chemotherapies don not have good efficacy.
The fact that diseases like MS, RA and many others have no cure creates
a huge unmet need. This trend has its advantages and disadvantages. For
the pharmaceutical company it opens a huge scope for R&D yet it reduces
the market growth as the patients prefer alternative therapies.
Scope
The scope of this report includes: